Eton Pharmaceuticals (ETON) Non-Current Assets (2017 - 2026)
Eton Pharmaceuticals (ETON) posted Non-Current Assets of $31.5 million for Q4 2025, down 3.01% sequentially from $32.5 million in Q3 2025, and down 10.17% YoY from $35.1 million in Q4 2024.
Eton Pharmaceuticals (ETON) Non-Current Assets (2017 - 2026) Analysis & Trends
Eton Pharmaceuticals has reported Non-Current Assets for 9 years, with the latest figure at $31.5 million in Q4 2025.
- Quarterly Non-Current Assets fell 10.17% year-over-year to $31.5 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $131.3 million (up 142.72% YoY) and the FY2025 annual result came in at $31.5 million, down 10.17% from the prior year.
- Non-Current Assets slipped to $31.5 million in Q4 2025 per ETON's latest filing, from $32.5 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $35.1 million in Q4 2024 and troughed at $743000.0 in Q3 2021.
- A 5-year average of $11.4 million and a median of $5.0 million in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2021 and 2024: Non-Current Assets sank 53.85% in 2021, then soared 616.22% in 2024.
- Over 5 years, Non-Current Assets stood at $3.9 million in 2021, then soared by 30.17% to $5.0 million in 2022, then declined by 2.49% to $4.9 million in 2023, then jumped by 616.22% to $35.1 million in 2024, then decreased by 10.17% to $31.5 million in 2025.
- According to Business Quant data, Non-Current Assets over the past three periods registered $31.5 million, $32.5 million, and $33.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | 37.96 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 26.10 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 8.72 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 78.51 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 3.74 Bn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 24.99 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 3.72 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 9.76 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 2.96 Bn |
| 10 | Eton Pharmaceuticals | 1.65 Bn | 1.62 Bn | 25.41 Mn | 47.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 47.21 Mn |
| Dec 31, 2025 | 31.53 Mn |
| Sep 30, 2025 | 32.51 Mn |
| Jun 30, 2025 | 33.23 Mn |
| Mar 31, 2025 | 34.07 Mn |
| Dec 31, 2024 | 35.10 Mn |
| Sep 30, 2024 | 6.09 Mn |
| Jun 30, 2024 | 6.39 Mn |
| Mar 31, 2024 | 6.53 Mn |
| Dec 31, 2023 | 4.90 Mn |
| Sep 30, 2023 | 4.37 Mn |
| Jun 30, 2023 | 4.60 Mn |
| Mar 31, 2023 | 4.81 Mn |
| Dec 31, 2022 | 5.03 Mn |
| Sep 30, 2022 | 5.10 Mn |
| Jun 30, 2022 | 3.27 Mn |
| Mar 31, 2022 | 4.45 Mn |
| Dec 31, 2021 | 3.86 Mn |
| Sep 30, 2021 | 743,000.00 |
| Jun 30, 2021 | 831,000.00 |